The newly merged company also formed a subsidiary known as Sanofi Pasteur, which is today one of the world’s largest producers of vaccinations for a variety of conditions, including tetanus ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

At close: October 11 at 5:35 PM GMT+2 ...

The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines.

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday. The FDA has approved Sarclisa ...

By Michael Erman NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not ...

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private ...

Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially. The French pharma group confirmed ...

Sanofi has stopped a phase 2 trial of Denali ... and placebo on serum neurofilament levels. Neurofilament light chain (NfL) is a neurodegenerative disease biomarker. A drop in NfL could reflect ...

The stock of Sanofi ADR (SNY) has gone down by -0.44% for the week, with a -4.74% drop in the past month and a 8.76% rise in the past quarter. The volatility ratio for the week is 1.30%, and the ...